Abstract
We describe the design, synthesis, and structure-activity relationships (SARs) of a series of 2-aminobenzothiazole inhibitors of Rho kinases (ROCKs) 1 and 2, which were optimized to low nanomolar potencies by use of protein kinase A (PKA) as a structure surrogate to guide compound design. A subset of these molecules also showed robust activity in a cell-based myosin phosphatase assay and in a mechanical hyperalgesia in vivo pain model.
Keywords:
benzothiazoles; inhibitors; kinases; structure-activity relationships.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Benzothiazoles / chemical synthesis
-
Benzothiazoles / chemistry
-
Benzothiazoles / pharmacology*
-
Crystallography, X-Ray
-
Dose-Response Relationship, Drug
-
Drug Design*
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Structure-Activity Relationship
-
rho-Associated Kinases / antagonists & inhibitors*
-
rho-Associated Kinases / metabolism
Substances
-
Benzothiazoles
-
Protein Kinase Inhibitors
-
aminobenzothiazole compound
-
rho-Associated Kinases